S. Khoo

发表

Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England

Sally James, K. Seden, J. Kirkham, 2013, BMJ Open.

The intracellular pharmacology of antiretroviral protease inhibitors.

S. Khoo, J. Ford, D. Back, 2004, The Journal of antimicrobial chemotherapy.

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy

M. García-Fiñana, R. Kolamunnage-Dona, J. Whitehead, 2015, BMJ Open.

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy

M. García-Fiñana, R. Kolamunnage-Dona, C. Leen, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

M. Battegay, C. Marzolini, S. Khoo, 2020, The Journal of antimicrobial chemotherapy.

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

Kaleab Z. Abebe, S. Khoo, C. Dezzutti, 2016, The lancet. HIV.

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults

S. Khoo, E. Katabira, M. Boffito, 2011, Chemotherapy research and practice.

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, medRxiv.

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, medRxiv.

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, British journal of clinical pharmacology.

Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.

S. Khoo, E. Jones, A. Owen, 2007, The Journal of antimicrobial chemotherapy.

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease

S. Khoo, H. Kinvig, M. Siccardi, 2022, Frontiers in Pharmacology.

Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding

S. Khoo, A. Owen, M. Siccardi, 2018 .

Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation

Darren L. Smith, Tom O. McDonald, S. Khoo, 2014, Advanced healthcare materials.

Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.

I. Bruce, S. Hider, S. Khoo, 2005, Arthritis and rheumatism.

Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

N. Beeching, S. Khoo, D. Back, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers

S. Khoo, K. Seng, L. Lee, 2015, Antimicrobial Agents and Chemotherapy.

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

T. Harrer, J. van Lunzen, M. Vogel, 2008, The Journal of antimicrobial chemotherapy.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

M. Youle, M. Johnson, J. Rockstroh, 2011, The Journal of antimicrobial chemotherapy.

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine

S. Khoo, J. Tarning, P. Byakika-Kibwika, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid)

S. Khoo, D. Back, Stephen Taylor, 2011, Antiviral therapy.

Inflammatory Phenotypes Predict Changes in Arterial Stiffness Following Antiretroviral Therapy Initiation

W. Tinago, S. Khoo, R. Heyderman, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacogenetics of antiretroviral agents

S. Khoo, A. Owen, 2008, Current opinion in HIV and AIDS.

Pharmacogenetics of HIV therapy

M. Pirmohamed, S. Khoo, A. Owen, 2006, Pharmacogenetics and genomics.

An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

S. Khoo, S. Parikh, M. Lemnge, 2020, Antimicrobial Agents and Chemotherapy.

Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies

S. Khoo, A. Owen, M. Boffito, 2013, Journal of acquired immune deficiency syndromes.

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

S. Khoo, U. Lalloo, G. Friedland, 2006, The Journal of antimicrobial chemotherapy.

Ageing with HIV: medication use and risk for potential drug-drug interactions.

R. Weber, M. Battegay, H. Furrer, 2011, The Journal of antimicrobial chemotherapy.

Optimal sampling strategies for early pharmacodynamic measures in tuberculosis.

L. Aarons, S. Khoo, G. Davies, 2006, The Journal of antimicrobial chemotherapy.

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

M. Youle, S. Khoo, C. Smith, 2009, HIV medicine.

Current uses and future hopes for clinical pharmacology in the management of HIV infection

S. Khoo, D. Back, S. Gibbons, 2000, HIV medicine.

Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

S. Khoo, D. Back, L. Dickinson, 2010, Antiviral research.

Tenofovir disoproxil fumarate and the kidney in HIV-infected patients: the evidence thus far.

M. Pirmohamed, S. Khoo, M. Danjuma, 2010 .

A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin.

S. Khoo, D. Back, S. Ward, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Doravirine: its role in HIV treatment

S. Khoo, A. Stockdale, 2021, Current opinion in HIV and AIDS.

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

C. Marzolini, S. Khoo, Catherine E Moss, 2019, Clinical Pharmacokinetics.

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.

S. Khoo, D. Back, L. Almond, 2005, The Journal of antimicrobial chemotherapy.

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi

M. Pirmohamed, S. Khoo, R. Heyderman, 2013, Antimicrobial Agents and Chemotherapy.

Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women

S. Khoo, C. Nakabiito, M. Boffito, 2010, Journal of acquired immune deficiency syndromes.

Associations of Hepatosteatosis With Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV–Heart Project

S. Ortega-Martorell, S. Khoo, T. Heseltine, 2021, Journal of acquired immune deficiency syndromes.

Intrapulmonary pharmacokinetics of first-line anti-TB drugs in Malawian tuberculosis patients.

S. Khoo, G. Davies, D. Sloan, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis

S. Khoo, G. Davies, D. Sloan, 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

S. Khoo, Chloe E. James, A. Owen, 2010, Pharmacogenetics and genomics.

Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.

S. Khoo, A. Owen, D. Back, 2009, British journal of clinical pharmacology.

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

T. Jaki, S. Khoo, S. Ewings, 2020, Trials.

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

W. Greenhalf, T. Jaki, S. Khoo, 2021, The Journal of antimicrobial chemotherapy.

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

T. Fletcher, W. Greenhalf, T. Jaki, 2021, medRxiv.

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

D. Cooper, P. Phanuphak, S. Khoo, 2015, Clinical Pharmacokinetics.

Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.

S. Khoo, D. Back, H. Reynolds, 2015, The Journal of antimicrobial chemotherapy.

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV

A. Winston, C. Sabin, S. Khoo, 2021, PloS one.

Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.

S. Khoo, D. Back, P. Hoggard, 2001, British journal of clinical pharmacology.

The development and validation of a novel LC-MS/MS method for the quantification of Cenicriviroc in human plasma and cerebrospinal fluid.

A. Winston, S. Khoo, L. Else, 2019, Biomedical chromatography : BMC.

Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update)

C. Leen, A. Winston, C. Sabin, 2014 .

Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection

C. Marzolini, S. Khoo, J. V. van Oosterhout, 2021, Clinical Pharmacokinetics.

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

S. Khoo, A. Owen, J. Ford, 2003, Journal of acquired immune deficiency syndromes.

Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease

S. Khoo, F. Drobniewski, C. Snelson, 2010, Thorax.

British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV‐seropositive individuals 2011

B. Gazzard, N. Beeching, M. Singer, 2011, HIV medicine.

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

L. Myer, S. Khoo, C. Orrell, 2019, PLoS medicine.

British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019

C. Leen, K. Seden, S. Khoo, 2019, HIV medicine.

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

L. Myer, Duolao Wang, S. Khoo, 2022, AIDS Research and Therapy.

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.

T. Berg, I. Colle, S. Khoo, 2017, Journal of hepatology.

P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir

S. Khoo, P. Chiba, D. Back, 2009, Antiviral therapy.

Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4

S. Khoo, C. Hart, A. Owen, 2004, Journal of Virology.

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells

S. Khoo, O. Janneh, 2011, Pharmaceutics.

Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens

S. Pushpakom, S. Khoo, A. Owen, 2010 .

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.

S. Khoo, A. Owen, N. Liptrott, 2013, The Journal of antimicrobial chemotherapy.

The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High‐Density Lipoprotein Cholesterol in HIV‐Infected Patients Receiving Efavirenz

M. Youle, S. Khoo, C. Smith, 2009, Clinical pharmacology and therapeutics.

Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat

S. Khoo, M. Boffito, E. Elliot, 2019, HIV research & clinical practice.

Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.

S. Khoo, G. Coutts, P. Julyan, 2013, European journal of radiology.

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

C. Marzolini, S. Khoo, D. Back, 2016, The Journal of antimicrobial chemotherapy.

Pharmacokinetic Drug Interactions with Nevirapine

S. Khoo, D. Back, S. Gibbons, 2003, Journal of acquired immune deficiency syndromes.

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection

S. Khoo, S. Bhagani, D. Karageorgopoulos, 2014, Current opinion in infectious diseases.

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

N. Ford, G. Cooke, S. Khoo, 2015, Hepatology.

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies

C. Marzolini, S. Khoo, D. Back, 2020, The Journal of antimicrobial chemotherapy.

Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study.

C. Marzolini, S. Khoo, Carlos Badenes-Olmedo, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

S. Khoo, D. Back, M. Barry, 1997, Antimicrobial agents and chemotherapy.

‘I fear my partner will abandon me’: the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda

L. Myer, S. Khoo, H. Reynolds, 2022, BMC Pregnancy and Childbirth.

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults)

S. Khoo, I. Adetifa, D. Lalloo, 2022, Wellcome open research.

Enhanced and timely investigation of ARVs for use in pregnant women.

N. Ford, L. Mofenson, S. Khoo, 2020, Journal of acquired immune deficiency syndromes.

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites

A. Breckenridge, S. Khoo, D. Back, 1996, AIDS.

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis

H. Chu, R. Weinshilboum, A. Telenti, 2015, EBioMedicine.

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults

S. Khoo, M. Boffito, D. Back, 2012, AIDS research and treatment.

Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.

S. Khoo, M. Boffito, D. Back, 2011, The Journal of antimicrobial chemotherapy.

Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

V. Soriano, H. McLeod, S. Khoo, 2010, Antimicrobial Agents and Chemotherapy.

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.

Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or Without Cirrhosis

S. Khoo, P. Duca, D. Back, 2008, Therapeutic drug monitoring.

Safety and efficacy of combined meningococcal and typhoid vaccine

S. Khoo, B. Mandal, J. Roberts, 1995, BMJ.

Open source clinical science for emerging infections

P. Horby, D. Angus, J. Farrar, 2013, The Lancet Infectious Diseases.

Clinical and population‐based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy

B. Chi, J. Stringer, L. Myer, 2022, Journal of the International AIDS Society.

Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents

S. Khoo, H. McIlleron, 2011 .

Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling

S. Khoo, A. Owen, A. Schipani, 2018, The Journal of antimicrobial chemotherapy.

Pharmacogenetics of pregnancy‐induced changes in efavirenz pharmacokinetics

S. Khoo, A. Owen, L. Else, 2015, Clinical pharmacology and therapeutics.

Estimation of the Effect of Slco1B1 Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults

M. Youle, S. Khoo, A. Owen, 2012, Antiviral therapy.

Limited-Sampling Strategy for the Prediction of Boosted Hard-Gel Saquinavir Exposure at a Dosage of 1000/100 mg Twice Daily in Human Immunodeficiency Virus-Infected Individuals

S. Khoo, M. Boffito, D. Back, 2007, Therapeutic drug monitoring.

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus‐infected individuals

S. Khoo, D. Back, L. Almond, 2005, Clinical pharmacology and therapeutics.

Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna

S. Khoo, A. Owen, D. Back, 2004, Antiviral therapy.

CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers

S. Khoo, A. Owen, J. Tarning, 2019, Journal of clinical pharmacology.

Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes

M. Pirmohamed, S. Khoo, D. Back, 2002, Antiviral therapy.

An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database)

S. Khoo, M. Danjuma, Nurul H Mohamad-Fadzillah, 2014, International journal of STD & AIDS.

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults

S. Khoo, P. D. de Vries, E. Katabira, 2012, The Journal of antimicrobial chemotherapy.

Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.

S. Khoo, D. Lalloo, I. Hastings, 2007, AIDS.

Will ART rollout in Africa drive an epidemic of drug resistant HIV?

S. Khoo, D. Lalloo, I. Hastings, 2006, AIDS.

Cardiovascular computed tomography and HIV: The evolving role of imaging biomarkers in enhanced risk prediction

S. Khoo, T. Heseltine, B. Ruzsics, 2021, Imaging.

Drug–drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases

K. Seden, S. Khoo, D. Back, 2013, AIDS.

Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria

S. Khoo, B. Taiwo, B. Berzins, 2022, AIDS Research and Therapy.

Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings

S. Khoo, D. Mitchison, Jenny Allen, 2012, Journal of Clinical Microbiology.

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

S. Khoo, A. Owen, D. Back, 2014, Pharmacogenetics & Genomics.

Weight gain stopping/switch rules for antiretroviral clinical trials.

M. Siedner, E. Delaporte, S. Khoo, 2021, AIDS.

Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study

S. Khoo, S. Emery, R. Puls, 2011, Antimicrobial Agents and Chemotherapy.

The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva

S. Khoo, Rebecca L. Lyons, L. Else, 2021, Journal of pharmaceutical and biomedical analysis.

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment

C. Marzolini, S. Khoo, D. Back, 2020, Drugs in R&D.

Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?

J. Stewart, S. Khoo, J. Hiscox, 2021, The Journal of antimicrobial chemotherapy.

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

C. Marzolini, S. Khoo, D. Back, 2020, British Journal of Clinical Pharmacology.

Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?

S. Khoo, E. Nsutebu, Abdullah AlAkhras, 2020, Postgraduate Medical Journal.

Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

Jordan J. Clark, Michael J. Murphy, Megan L. Nagel, 2021, The Lancet Respiratory Medicine.

Increasing use of ‘party drugs’ in people living with HIV on antiretrovirals: a concern for patient safety

D. Stuart, S. Khoo, M. Boffito, 2015, AIDS.

Pharmacokinetics of Zidovudine Phosphorylation in Human Immunodeficiency Virus-Positive Thai Patients and Healthy Volunteers

S. Khoo, D. Back, J. Karbwang, 2000, Antimicrobial Agents and Chemotherapy.

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes

S. Khoo, A. Owen, J. Tarning, 2019, Antimicrobial Agents and Chemotherapy.

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue

S. Khoo, C. Herrera, N. Martinson, 2022, Pharmaceutics.

The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis

S. Khoo, M. von Kleist, L. Dickinson, 2019, Front. Pharmacol..

Cerebrospinal fluid exposure of cenicriviroc in HIV‐positive individuals with cognitive impairment

A. Winston, S. Khoo, L. Else, 2019, British journal of clinical pharmacology.

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

S. Khoo, D. Back, S. Ouwerkerk-Mahadevan, 2018, British journal of clinical pharmacology.

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

S. Khoo, A. Owen, D. Back, 2015, The Journal of antimicrobial chemotherapy.

In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy.

S. Khoo, D. Back, M. Barry, 1997, AIDS research and human retroviruses.

An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs

S. Khoo, D. Back, S. Gibbons, 2006, Therapeutic drug monitoring.

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia

C. Leen, M. Pirmohamed, L. Haddow, 2016, Journal of NeuroVirology.

Effect of Transporter Modulation on the Emergence of Nelfinavir Resistance In Vitro

P. Cane, S. Khoo, A. Owen, 2007, Antiviral therapy.

Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support

S. Khoo, D. Back, P. Flegg, 2006, Journal of acquired immune deficiency syndromes.

The relationship between nevirapine plasma concentrations and abnormal liver function tests.

S. Khoo, G. di Perri, M. Boffito, 2004, AIDS research and human retroviruses.

The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.

S. Khoo, D. Burger, O. El-sherif, 2018, Annals of hepatology.

Intracellular metabolism of zidovudine and stavudine in combination.

S. Khoo, D. Back, P. Hoggard, 1996, The Journal of infectious diseases.

“It’s only fatness, it doesn’t kill”: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda

L. Myer, S. Khoo, H. Reynolds, 2022, BMC Women's Health.

Impact of efavirenz , ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on 1 the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-2 negative HIV-infected Malawian adults stabilized on antiretroviral therapy 3 4

S. Khoo, D. Terlouw, D. Lalloo, 2018 .

Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults.

S. Khoo, K. Seng, L. Lee, 2015, The Journal of antimicrobial chemotherapy.

Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials.

M. Siedner, E. Delaporte, S. Khoo, 2022, AIDS.

Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication

C. Leen, D. Pillay, A. Winston, 2008, Antiviral therapy.

Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa

P. Kaleebu, S. Khoo, C. Herrera, 2022, Frontiers in Immunology.

Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.

S. Khoo, L. Dickinson, M. Siccardi, 2019, Pharmacogenomics.

The Observed Effect of Gastric Bypass Surgery on the Treatment of Chronic Hepatitis C Virus (HCV) Infection; A Case Report

S. Khoo, D. Burger, O. El-sherif, 2017 .

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

D. Kuritzkes, C. Flexner, C. Marzolini, 2022, Clinical pharmacology and therapeutics.

Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman

R. Krüger, S. Khoo, C. Feiterna-Sperling, 2019, AIDS.

Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman

R. Krüger, S. Khoo, C. Feiterna-Sperling, 2019, AIDS.

Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.

A. Winston, S. Khoo, D. Back, 2013, The Journal of antimicrobial chemotherapy.

Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells.

S. Khoo, A. Owen, J. Ford, 2003, The Journal of infectious diseases.

Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients

S. Khoo, K. Jones, D. Back, 2002, Antimicrobial Agents and Chemotherapy.

An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

S. Khoo, S. Parikh, M. Lemnge, 2020, Antimicrobial Agents and Chemotherapy.

Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters

S. Khoo, F. Post, M. Danjuma, 2018, International journal of STD & AIDS.

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.

L. Myer, Duolao Wang, K. Seden, 2020, The lancet. HIV.

Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

H. Rees, S. Khoo, S. Lockman, 2019, Journal of the International AIDS Society.

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects

N. Ford, A. Phillips, L. Mofenson, 2019, Journal of the International AIDS Society.

T cell Homeostatic Imbalance in Placentae from Women with HIV in the absence of Vertical Transmission

L. Myer, C. Gray, S. Khoo, 2021 .

Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1

L. Myer, S. Khoo, C. Orrell, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

L. Myer, S. Khoo, C. Orrell, 2018, Bioanalysis.

DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy

L. Myer, S. Khoo, C. Orrell, 2018 .

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study

S. Khoo, S. Emery, J. Amin, 2017, Therapeutic drug monitoring.

Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies

S. Khoo, P. Garner, L. Bonnett, 2015, The Journal of antimicrobial chemotherapy.

Short-term oral pre-exposure prophylaxis against HIV-1 modulates the transcriptome of foreskin tissue in young men in Africa

P. Kaleebu, S. Khoo, C. Herrera, 2022, Frontiers in Immunology.

In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with Mefloquine

S. Khoo, C. Hart, A. Owen, 2005, Journal of Pharmacology and Experimental Therapeutics.

Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients

S. Khoo, D. Back, F. Rousseau, 2003, Antimicrobial Agents and Chemotherapy.

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

S. Khoo, R. Wood, D. Back, 2002, AIDS.

Pharmacokinetic interactions of modern antiretroviral therapy

S. Khoo, M. Boffito, P. Sinxadi, 2021, AIDS.

Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects

B. Gazzard, S. Khoo, M. Boffito, 2012, Antiviral therapy.

Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.

I. Williams, P. Newton, S. Khoo, 2003, The Journal of antimicrobial chemotherapy.

Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo.

S. Khoo, D. Back, P. Hoggard, 2002, Journal of immunological methods.

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.

S. Khoo, A. Owen, D. Back, 2015, The Journal of antimicrobial chemotherapy.

Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry.

S. Khoo, M. Boffito, D. Back, 2014, Bioanalysis.

Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer.

S. Khoo, D. Back, L. Else, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Global outbreak research: harmony not hegemony

P. Horby, J. Marshall, D. Angus, 2020, The Lancet Infectious Diseases.

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

S. Khoo, P. Chiba, E. Jones, 2010, The Journal of antimicrobial chemotherapy.

Novel IFN-alpha receptor promoter polymorphisms.

W. Ollier, A. Hajeer, S. Khoo, 2001, Genes and immunity.

Clinical features and management of human monkeypox: a retrospective observational study in the UK

Jennifer L. Small, N. Beeching, T. Fletcher, 2022, The Lancet. Infectious diseases.

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.

L. Myer, Duolao Wang, K. Seden, 2022, The lancet. HIV.

Advancing knowledge in perinatal HIV treatment.

L. Myer, S. Khoo, C. Waitt, 2020, The lancet. HIV.

Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans

S. Khoo, D. Lalloo, R. Parkes-Ratanshi, 2009, Journal of Antimicrobial Chemotherapy.

Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology.

S. Khoo, J. D. de Jong, B. Mandal, 1995, The Journal of infectious diseases.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

Sheena McCormack, Anne M Johnson, Christine Bowman, 2016, The Lancet.

Second European Round Table on the Future Management of HIV

M. Altfeld, D. Richman, B. Clotet, 2015, Journal of virus eradication.

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015

C. Leen, A. Winston, C. Sabin, 2016, HIV medicine.

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)

C. Leen, A. Winston, C. Sabin, 2014, HIV medicine.

7.0 Managing virological failure

C. Leen, A. Winston, C. Sabin, 2012, HIV medicine.

Dosing antiretroviral medication when crossing time zones: a review

S. Khoo, M. Boffito, A. Volny-Anne, 2016, AIDS.

Controversies in HIV-associated neurocognitive disorders

A. Winston, S. Khoo, J. McArthur, 2014, The Lancet Neurology.

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

C. Marzolini, S. Khoo, D. Back, 2021, Clinical Pharmacokinetics.

Pharmacokinetics of Reverse Transcriptase Inhibitors

S. Khoo, D. Back, P. Hoggard, 2006 .

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

E. Hadley, K. Hood, B. Jani, 2022, SSRN Electronic Journal.

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

N. Ford, S. Khoo, Bryony Simmons, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.

S. Khoo, A. Owen, D. Back, 2009, The Journal of antimicrobial chemotherapy.

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

B. Gazzard, S. Khoo, J. Ford, 2006, The Journal of antimicrobial chemotherapy.

Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients

B. Gazzard, S. Khoo, J. Ford, 2004, Antimicrobial Agents and Chemotherapy.

A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets.

S. Khoo, A. Owen, J. Ford, 2003, Journal of immunological methods.

Grapefruit-Drug Interactions

Laura Dickinson, David Back, Saye Khoo, 2010, Drugs.

Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease.

R. Paredes, S. Khoo, A. Curran, 2022, The Journal of antimicrobial chemotherapy.

Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease

B. Clotet, S. Khoo, F. Graterol, 2016, Antimicrobial Agents and Chemotherapy.

Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, Clinical pharmacology and therapeutics.

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria

S. Khoo, K. Robertson, B. Taiwo, 2021, AIDS.

Two cases of monkeypox imported to the United Kingdom, September 2018

Jennifer Wilburn, Roberto Vivancos, Nick Harper, 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling

S. Khoo, R. Bearon, M. Siccardi, 2022, Frontiers in Pharmacology.

Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?

A. Winston, S. Khoo, 2008, Current opinion in HIV and AIDS.

An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2

Michael Fisher, T. Jaki, S. Khoo, 2021, medRxiv.

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

S. Khoo, A. Owen, H. Pertinez, 2021, The Journal of antimicrobial chemotherapy.

Therapeutic drug Monitoring of Darunavir/Ritonavir in Pregnancy

V. Jackson, J. Lambert, S. Khoo, 2019, Antiviral therapy.

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

S. Khoo, A. Owen, M. Siccardi, 2017, Antimicrobial Agents and Chemotherapy.

Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

Marco Siccardi, Andrew Owen, David Back, 2013, Clinical Pharmacokinetics.

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

L. Aarons, R. Autar, S. Khoo, 2008, The Journal of antimicrobial chemotherapy.

A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography–Mass Spectrometry

S. Khoo, R. Puls, D. Back, 2015, Therapeutic drug monitoring.

Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.

S. Khoo, D. Back, C. Merry, 2015, The Journal of antimicrobial chemotherapy.

Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.

Mark Hopkins, S. Khoo, J. V. van Oosterhout, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.

David Back, Saye Khoo, K. Seden, 2010, The Journal of antimicrobial chemotherapy.

Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother–infant pairs

S. Khoo, A. Owen, M. Lamorde, 2018, The Journal of antimicrobial chemotherapy.

Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC–MS/MS

S. Khoo, M. Lamorde, L. Else, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Zidovudine phosphorylation and mitochondrial toxicity in vitro.

S. Khoo, C. Hart, D. Back, 2001, Toxicology and applied pharmacology.

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

D. Cooper, P. Phanuphak, S. Khoo, 2015, Clinical pharmacology and therapeutics.

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?

S. Khoo, M. Boffito, D. Back, 2014, Journal of the International AIDS Society.

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

S. Khoo, P. D. de Vries, E. Katabira, 2012, The Journal of antimicrobial chemotherapy.

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.

L. Aarons, S. Khoo, M. Boffito, 2008, The Journal of antimicrobial chemotherapy.

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

S. Khoo, D. Back, L. Dickinson, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

B. Gazzard, S. Khoo, N. Liptrott, 2011, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract

S. Khoo, D. Back, Stephen Taylor, 2011, Antiviral therapy.

Plasma Pharmacokinetics of Once- versus Twice-Daily Lamivudine and Abacavir: Simplification of Combination Treatment in HIV-1-Infected Children (Penta-13)

S. Khoo, D. Gibb, H. Lyall, 2005, Antiviral therapy.

Therapeutic drug monitoring as a tool in treating HIV infection.

S. Khoo, D. Back, S. Gibbons, 2001, AIDS.

Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively

S. Khoo, J. D. de Jong, P. W. Wertheim-van Dillen, 1999, Journal of Clinical Microbiology.

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

Max von Kleist, Sulav Duwal, Laura Dickinson, 2019, PLoS Comput. Biol..

Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes

Max von Kleist, Sulav Duwal, Laura Dickinson, 2018, PLoS Comput. Biol..

Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.

S. Khoo, D. Holt, S. T. Sadiq, 2005, AIDS.

The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

S. Khoo, M. Boffito, D. Back, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

S. Khoo, D. Back, M. Siccardi, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval

S. Khoo, G. di Perri, M. Boffito, 2004, Therapeutic drug monitoring.

Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30® tablets

S. Khoo, D. Burger, E. Molyneux, 2010, Antiviral therapy.

Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.

S. Khoo, G. di Perri, M. Boffito, 2008, The Journal of antimicrobial chemotherapy.

The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report.

S. Khoo, D. Burger, O. El-sherif, 2018, Annals of hepatology.

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

S. Khoo, D. Back, L. Dickinson, 2008, Current opinion in HIV and AIDS.

Divalent Metals and pH Alter Raltegravir Disposition In Vitro

S. Khoo, A. Owen, D. Back, 2012, Antimicrobial Agents and Chemotherapy.

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors.

M. Battegay, M. Cavassini, C. Marzolini, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

N. Ford, S. Khoo, A. Hill, 2016, Journal of the International AIDS Society.

Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan Adults

S. Khoo, M. Boffito, D. Back, 2012, Journal of acquired immune deficiency syndromes.

Stopping antiretroviral therapy

S. Khoo, M. Boffito, D. Back, 2007, AIDS.

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Munir Pirmohamed, Andrew Owen, Thomas Jaki, 2021, Trials.

HIV infection and stroke: current perspectives and future directions

S. Khoo, M. Connor, A. Bryer, 2012, The Lancet Neurology.

Combining resistance and pharmacology for optimum patient care

A. Winston, S. Khoo, D. Back, 2007, Current opinion in HIV and AIDS.

Key drug–drug interactions with direct-acting antiviral in HIV–HCV coinfection

S. Khoo, C. Solas, O. El-sherif, 2015, Current opinion in HIV and AIDS.

Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.

H. Jessen, A. Winston, D. Cooper, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.

S. Khoo, F. Sarfo, A. Owen, 2014, The Journal of antimicrobial chemotherapy.

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

L. Aarons, S. Khoo, L. Waters, 2009, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2008, Antiviral therapy.

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort

K. Seden, S. Khoo, S. Kimaiyo, 2011, PloS one.

Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

S. Khoo, C. Fletcher, D. Back, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites

D. Haas, G. Maartens, S. Khoo, 2018, The Journal of antimicrobial chemotherapy.

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

K. Seden, S. Khoo, M. Lamorde, 2018, The Journal of antimicrobial chemotherapy.

Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries

K. Seden, S. Khoo, M. Boffito, 2017, Current opinion in HIV and AIDS.

Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine

S. Khoo, A. Owen, D. Back, 2014, Clinical Pharmacokinetics.

Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.

C. Yiannoutsos, S. Khoo, K. Wools-Kaloustian, 2021 .

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.

A. Waldman, A. Winston, S. Khoo, 2014, The Journal of antimicrobial chemotherapy.

Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population

P. Deloukas, A. Morris, M. Nelson, 2017, The Journal of antimicrobial chemotherapy.

CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations

M. Pirmohamed, S. Khoo, R. Heyderman, 2014, The Journal of antimicrobial chemotherapy.

Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population

M. Pirmohamed, S. Khoo, R. Heyderman, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals

S. Khoo, A. Owen, D. Back, 2006, Clinical pharmacokinetics.

Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports

S. Khoo, J. Fox, D. Back, 2016, Infectious Diseases and Therapy.

Darunavir pharmacokinetics throughout pregnancy and postpartum

V. Jackson, M. Lawless, J. Lambert, 2014, Journal of the International AIDS Society.

Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis.

S. Khoo, A. Owen, A. Olagunju, 2016, Pharmacogenomics.

Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.

S. Khoo, A. Owen, D. Back, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Exposure of Breastfed Infants to Maternal Efavirenz from Breast Milk

S. Khoo, A. Owen, M. Siccardi, 2013 .

The potential for interactions between antimalarial and antiretroviral drugs

David Back, Saye Khoo, S. Khoo, 2005, AIDS.

Short Communication: Expression of P-Glycoprotein and Multidrug Resistance-Associated Protein in Healthy Volunteers and HIV-Infected Patients

S. Khoo, D. Back, P. Hoggard, 2001 .

Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation.

S. Khoo, D. Back, M. Barry, 1996, AIDS.

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.

S. Khoo, G. di Perri, A. Owen, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects.

S. Khoo, A. Owen, D. Back, 2007, The Journal of antimicrobial chemotherapy.

Intracellular Indinavir Pharmacokinetics in HIV-Infected Patients: Comparison with Plasma Pharmacokinetics

S. Khoo, D. Back, M. Barry, 2002, Antiviral therapy.

Therapeutic drug monitoring of anti-HIV drugs

S. Khoo, D. Back, C. Merry, 2001 .

The role of therapeutic drug monitoring in treatment of HIV infection.

S. Khoo, D. Back, C. Merry, 2001, British journal of clinical pharmacology.

Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection.

S. Khoo, D. Back, C. Merry, 2000, Therapeutic drug monitoring.

Efficacy and safety of dihydroartemisinin–piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial

S. Khoo, D. Terlouw, D. Lalloo, 2019, Malaria Journal.

Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?

S. Khoo, A. Owen, M. T. Bakare-Odunola, 2019, British journal of clinical pharmacology.

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection

Catia Marzolini, Saye H. Khoo, David M. Burger, 2017, PloS one.

Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment

S. Khoo, D. Back, M. Ryan, 2013, AIDS.

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.

S. Khoo, G. di Perri, M. Boffito, 2003, AIDS.

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge

S. Khoo, M. Boffito, G. Moyle, 2017, The Journal of antimicrobial chemotherapy.

Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations

S. Khoo, D. Back, L. Dickinson, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

B. Gazzard, S. Khoo, S. Emery, 2011, The Journal of antimicrobial chemotherapy.

Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir

V. Jackson, S. Khoo, M. Chaponda, 2011, International journal of STD & AIDS.

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

S. Khoo, W. Fraser, D. Back, 2009, The Journal of antimicrobial chemotherapy.

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

L. Aarons, S. Khoo, M. Boffito, 2011, Antimicrobial Agents and Chemotherapy.

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

S. Khoo, S. Anderson, S. Urien, 2011, British journal of clinical pharmacology.

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.

A. Winston, S. Khoo, M. Boffito, 2016, The Journal of antimicrobial chemotherapy.

Intracellular pharmacokinetics of antiretroviral agents.

S. Khoo, A. Owen, 2004, Journal of HIV therapy.

Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors

N. Beeching, I. Williams, P. Newton, 2002, Antimicrobial Agents and Chemotherapy.

Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression

W. Ollier, A. Hajeer, S. Khoo, 1997, AIDS.

Safety perspectives on presently considered drugs for the treatment of COVID‐19

Amy E. Chadwick, M. Pirmohamed, S. Khoo, 2020, British journal of pharmacology.

Genome-Wide Association Study of Nevirapine Hypersensitivity in a sub-Saharan 1 African HIV-infected Population 2 3

Munir, Elizabeth, Pirmohamed, 2016 .

Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.

K. Seden, S. Khoo, D. Back, 2013, The Journal of antimicrobial chemotherapy.

Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.

S. Khoo, A. Owen, D. Back, 2007, Tuberculosis.

Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020

Jordan J. Clark, Michael J. Murphy, Megan L. Nagel, 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.

S. Khoo, A. Owen, M. Boffito, 2016, The Journal of antimicrobial chemotherapy.

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

Jordan J. Clark, Michael J. Murphy, Megan L. Nagel, 2021, The Lancet. Microbe.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

M. Pirmohamed, S. Pushpakom, S. Khoo, 2012, Pharmacogenetics and genomics.

Efficacy and safety of artemether–lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial

S. Khoo, D. Terlouw, D. Lalloo, 2019, Malaria Journal.

Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment

L. Aarons, S. Khoo, R. Brindle, 2006, Antimicrobial Agents and Chemotherapy.

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.

S. Khoo, D. Carr, A. Owen, 2020, The Journal of antimicrobial chemotherapy.

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Nigel de Kare-Silver, S. Royal, K. Hood, 2022, The Lancet.

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

W. Greenhalf, S. Khoo, D. Lalloo, 2022, Nature Communications.

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Jonathon P. Baker, F. Hayden, W. Greenhalf, 2022, The Lancet Infectious Diseases.

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2

S. Khoo, A. Owen, H. Pertinez, 2021, medRxiv.

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis

J. Farrar, M. Pirmohamed, A. Winston, 2016, Antimicrobial Agents and Chemotherapy.

Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.

K. Seden, S. Khoo, D. Back, 2009, The Journal of antimicrobial chemotherapy.

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

S. Khoo, D. Gibb, T. Cressey, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.

P. Cane, S. Khoo, D. Back, 2004, The Journal of antimicrobial chemotherapy.

A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.

S. Khoo, S. Ward, A. Schipani, 2016, British journal of clinical pharmacology.

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

S. Khoo, D. Back, S. Cohn, 2014, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study

G. Maartens, S. Khoo, J. Joska, 2022, Journal of acquired immune deficiency syndromes.

The neurologic phenotype of South African patients with HIV-associated neurocognitive impairment.

S. Khoo, M. McCaul, N. Sacktor, 2020, Neurology. Clinical practice.

S. Khoo, R. Heyderman, N. Klein, 2019, The Journal of infectious diseases.

Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.

S. Khoo, A. Hill, G. Peytavin, 2017, AIDS Reviews.

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol

R. Cortese, A. Nicosia, V. Libri, 2017, Scientific Reports.

Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.

S. Khoo, G. di Perri, M. Boffito, 2003, AIDS research and human retroviruses.

Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges

J. Schapiro, S. Khoo, S. Bhagani, 2018, International journal of STD & AIDS.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug

A. Silman, I. Bruce, S. Hider, 2006, Annals of the rheumatic diseases.

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

S. Khoo, C. Herrera, J. Fox, 2021, The Journal of antimicrobial chemotherapy.

Impact of polypharmacy on antiretroviral prescription in people living with HIV

C. Mussi, M. Cesari, S. Khoo, 2017, Journal of Antimicrobial Chemotherapy.

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

D. Kuritzkes, C. Flexner, C. Marzolini, 2022, Annals of Internal Medicine.

Kidney transplantation in HIV-positive adults: the UK experience

S. Khoo, F. Post, S. Bhagani, 2014, International journal of STD & AIDS.

Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome

S. Khoo, R. Heyderman, A. Schipani, 2014 .

Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021

S. Khoo, H. Harvala, L. Else, 2023, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Who accesses PrEP? An analysis of baseline data in the PROUD pilot

A. Nardone, S. McCormack, A. Sullivan, 2014 .

Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019

S. Khoo, H. Harvala, S. Ijaz, 2021, Sexually Transmitted Infections.

Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa—study protocol for a mixed-methods study including a randomised controlled trial

J. Seeley, P. Kaleebu, S. Khoo, 2020, Trials.

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.

V. Soriano, S. Khoo, A. Owen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study

R. Weber, M. Battegay, H. Furrer, 2010, Antiviral therapy.

Limited Utility of Cardiovascular Risk Scores for People Living with HIV in Malawi

W. Tinago, S. Khoo, N. Klein, 2020 .

Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity

S. Khoo, F. Post, J. Levy, 2014, AIDS.

Pharmacokinetic evaluation of etravirine

S. Khoo, D. Back, L. Dickinson, 2010, Expert opinion on drug metabolism & toxicology.

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry [version 3; peer review: 1 approved, 1 approved with reservations]

S. Khoo, Shakir Atoyebi, E. Adejuyigbe, 2022 .

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry [version 1; peer review: 1 approved, 1 approved with reservations]

S. Khoo, Shakir Atoyebi, E. Adejuyigbe, 2022 .

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry [version 2; peer review: 1 approved, 1 approved with reservations]

S. Khoo, Shakir Atoyebi, E. Adejuyigbe, 2022 .

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

S. Khoo, Shakir Atoyebi, E. Adejuyigbe, 2021, Wellcome open research.

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation

S. Khoo, M. Boffito, D. Back, 2015, Antimicrobial Agents and Chemotherapy.

Available Agents: Contraindications and Potential Drug–Drug Interactions

S. Khoo, F. Marra, A. Boyle, 2021 .

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

D. Podzamczer, S. Khoo, J. Niubó, 2018, Journal of NeuroVirology.

P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

S. Khoo, D. Back, S. Ward, 2001, AIDS.

Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

S. Khoo, D. Back, R. Davey, 2001, AIDS.

Inflammatory pathways amongst people living with HIV in Malawi differ according to socioeconomic status

W. Tinago, S. Khoo, N. Klein, 2020, PloS one.

Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study

C. Rentsch, S. Khoo, A. Justice, 2021, The Lancet. Healthy longevity.

Fluvoxamine for the treatment of COVID-19

C. Marzolini, S. Khoo, F. Marra, 2022, The Lancet Global Health.

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

Darren L. Smith, S. Khoo, A. Owen, 2010, Antimicrobial Agents and Chemotherapy.

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.

M. Pirmohamed, V. Soriano, S. Pushpakom, 2011, The Journal of infectious diseases.

Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry.

S. Khoo, A. Owen, N. Liptrott, 2008, Journal of immunological methods.

Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification.

P. Cane, S. Khoo, A. Owen, 2007, The Journal of antimicrobial chemotherapy.

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

S. Khoo, C. Hart, A. Owen, 2005, AIDS.

Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria

S. Khoo, D. Back, J. Chiong, 2018, International journal of STD & AIDS.

Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines

S. Khoo, A. Owen, D. Back, 2003 .

Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines.

S. Khoo, A. Owen, D. Back, 2003, AIDS.

The role of clinical pharmacology in optimizing antiretroviral therapy.

S. Khoo, D. Back, 2003, British journal of clinical pharmacology.

P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.

I. Williams, P. Newton, S. Khoo, 2002, The Journal of antimicrobial chemotherapy.

Total and Unbound Bictegravir Concentrations and Viral Suppression in CSF of HIV-infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56).

D. Podzamczer, S. Khoo, S. Videla, 2019, The Journal of infectious diseases.

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis

S. Khoo, A. Owen, S. Ward, 2017, Antimicrobial Agents and Chemotherapy.

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

Jordan J. Clark, Michael J. Murphy, Megan L. Nagel, 2021, The Lancet Rheumatology.

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications

M. Battegay, C. Marzolini, S. Khoo, 2018, Antimicrobial Agents and Chemotherapy.

Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study

S. Khoo, A. Owen, D. Back, 2016, Pharmacogenetics and genomics.

Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study

C. Sabin, A. Sullivan, J. Baillie, 2020, SSRN Electronic Journal.

Genital Secretion HIV RNA Shedding in HIV-Positive Patients on Ritonavir-Boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-Sectional Sub-Study from the PIVOT Trial

N. Beeching, S. Khoo, A. Clarke, 2020, Antiviral therapy.

Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency

Dominic P. Williams, M. Pirmohamed, A. Breckenridge, 1996, AIDS.

No room for complacency on drug resistance in Africa

Ian M. Hastings, David G. Lalloo, Saye H. Khoo, 2006, Nature.

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy

A. Walker, S. Khoo, D. Gibb, 2007, AIDS.

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease

S. Khoo, H. Kinvig, M. Siccardi, 2021, Frontiers in Pharmacology.

Recent advances in tuberculosis: New drugs and treatment regimens.

S. Khoo, G. Davies, D. Sloan, 2013, Current respiratory medicine reviews.

Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis

S. Khoo, S. Ward, F. Kloprogge, 2020, Open forum infectious diseases.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients

B. Clotet, S. Khoo, A. Curran, 2018, The Journal of antimicrobial chemotherapy.

S. Khoo, D. Terlouw, D. Lalloo, 2019, Malaria Journal.

Treating Advanced HIV Infection

S. Khoo, M. Boffito, D. Back, 2003, Journal of acquired immune deficiency syndromes.

Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study

S. Khoo, G. Davies, D. Sloan, 2016, PloS one.

Estimated generic prices for novel treatments for drug-resistant tuberculosis

Frederick E. Nytko, G. Cooke, S. Khoo, 2017, The Journal of antimicrobial chemotherapy.

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Jordan J. Clark, Michael J. Murphy, Megan L. Nagel, 2021, The Lancet. Respiratory medicine.

Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults

S. Khoo, D. Terlouw, D. Lalloo, 2018, Antimicrobial Agents and Chemotherapy.

HIV Associated Neurocognitive Disorders (HAND) in Malawian Adults and Effect on Adherence to Combination Anti-Retroviral Therapy: A Cross Sectional Study

S. Khoo, K. Robertson, T. Solomon, 2014, PloS one.

BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022

C. Leen, A. Winston, C. Sabin, 2022, HIV medicine.

Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals

A. Winston, S. Khoo, A. Clarke, 2018, AIDS.

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF☆

C. Leen, M. Pirmohamed, L. Haddow, 2016, Cytokine.

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

C. Marzolini, S. Khoo, D. Back, 2020, British journal of clinical pharmacology.

Adequacy of Rifampin Absorption after Jejunostomy Tube Administration

M. Beadsworth, S. Khoo, G. Davies, 2016, Pharmacotherapy.

Therapeutic Drug Monitoring

S. Khoo, D. Back, S. Gibbons, 2002, Journal of the International Association of Physicians in AIDS Care.

Intracellular and Plasma Pharmacokinetics of Nelfinavir and M8 in HIV-Infected Patients: Relationship with P-Glycoprotein Expression

D. Cornforth, M. Johnson, S. Khoo, 2004, Antiviral therapy.

Circulating microparticles are increased amongst people presenting with HIV and advanced immune suppression in Malawi and correlate closely with arterial stiffness: a nested case control study

S. Khoo, R. Heyderman, A. Rapala, 2020, Wellcome open research.

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

S. Khoo, A. Owen, M. Boffito, 2019, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers

S. Khoo, A. Owen, M. Boffito, 2018, The Journal of antimicrobial chemotherapy.

Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial

D. Fuchs, A. Winston, S. Khoo, 2021, HIV research & clinical practice.

Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda

K. Seden, S. Khoo, D. Back, 2015, The Journal of antimicrobial chemotherapy.

General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data

S. Khoo, A. Akpan, R. Bearon, 2023, Clinical Pharmacokinetics.

Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis

S. Khoo, N. Garton, M. Barer, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

R. Shafer, J. Schapiro, S. Khoo, 2023, AIDS Research and Therapy.

Prevalence of Potentially Clinically Significant Drug–Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature

Duolao Wang, C. Marzolini, S. Khoo, 2023, Journal of acquired immune deficiency syndromes.

Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients

B. Clotet, S. Khoo, J. Moltó, 2008, Antimicrobial Agents and Chemotherapy.

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy

D. Richman, A. Phillips, S. Khoo, 2018, Open forum infectious diseases.

Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV.

A. Winston, C. Sabin, S. Khoo, 2020, AIDS (London).

Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals

S. Khoo, C. Merry, P. Byakika-Kibwika, 2011, Malaria research and treatment.

Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2

S. Khoo, A. Owen, N. Liptrott, 2010 .

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT

M. García-Fiñana, R. Kolamunnage-Dona, M. Pirmohamed, 2019, Efficacy and Mechanism Evaluation.

HIV infection and stroke.

S. Khoo, L. Benjamin, 2018, Handbook of clinical neurology.

Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma.

S. Khoo, H. Reynolds, J. Chiong, 2023, Journal of pharmaceutical and biomedical analysis.

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

B. Gazzard, C. Leen, A. Winston, 2013, The Journal of antimicrobial chemotherapy.

Serum measurements of soluble CD23 in HIV infection.

S. Khoo, B. Mandal, P. Wilson, 1993, Immunology.

Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial

J. Seeley, P. Kaleebu, S. Khoo, 2023, EBioMedicine.

Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS.

S. Khoo, H. Reynolds, L. Else, 2023, Bioanalysis.

Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.

S. Khoo, P. Denti, M. Lamorde, 2021, The Journal of antimicrobial chemotherapy.

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis

S. Khoo, C. Herrera, J. Fox, 2016, Journal of acquired immune deficiency syndromes.

Prevalence of drug interactions between antiretroviral and co - administered drugs in Kenya

S. Khoo, S. Kimaiyo, A. Owen, 2008 .

Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

W. Greenhalf, S. Khoo, S. Ewings, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV‐positive patients

S. Khoo, N. Snowden, P. Klapper, 2000, Journal of medical virology.

Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes

S. Khoo, G. Davies, D. Sloan, 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Carbamazepine intervention in a patient with efavirenz-induced liver injury.

S. Khoo, J. Drenth, R. van Crevel, 2019, AIDS.

A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops.

S. Khoo, L. Turtle, J. Lewis, 2014, AIDS.

Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda

L. Myer, S. Khoo, C. Orrell, 2020, BMC Public Health.

Novel IFN-α receptor promoter polymorphisms

S. Khoo, A. Uriel, W. Ollier, 2001, Genes and Immunity.

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB

S. Khoo, D. Sloan, S. Squire, 2016, European Respiratory Journal.

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy

Jackson, V. Jackson, J. Lambert, 2014, HIV medicine.

Invasive aspergillosis in patients with AIDS.

S. Khoo, D. Denning, D W Denning, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis.

N. Beeching, A. Breckenridge, S. Khoo, 1995, The Journal of antimicrobial chemotherapy.

Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda

L. Myer, S. Khoo, C. Orrell, 2020, BMC Health Services Research.

Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients.

S. Khoo, D. Back, P. Hoggard, 2001, AIDS research and human retroviruses.

Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.

B. Gazzard, A. Winston, S. Khoo, 2006, Journal of acquired immune deficiency syndromes.

Administering amphotericin B--a practical approach.

S. Khoo, D. Denning, S. Khoo, 1994, The Journal of antimicrobial chemotherapy.

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol

R. Cortese, A. Nicosia, V. Libri, 2017, Scientific Reports.

Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study

C. Yiannoutsos, S. Khoo, K. Wools-Kaloustian, 2023, AIDS Research and Therapy.

Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity

S. Khoo, F. Post, J. Levy, 2014, AIDS.

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

S. Khoo, D. Back, M. Siccardi, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019

C. Leen, K. Seden, S. Khoo, 2019, HIV medicine.

D. Podzamczer, S. Khoo, J. Niubó, 2018, Journal of NeuroVirology.

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals

S. Khoo, M. Boffito, D. Back, 2018, HIV clinical trials.

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.

S. Khoo, G. di Perri, M. Boffito, 2014, AIDS.

Once daily atazanavir / cobicistat and darunavir / cobicistat exposure over 72 hours post 1 dose in plasma , urine and saliva : contribution to drug pharmacokinetic knowledge . 2 3

S. Khoo, M. Boffito, L. Else, 2017 .

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.

S. Khoo, M. Boffito, G. Moyle, 2017, The Journal of antimicrobial chemotherapy.

Drug-drug Interactions between and Commonly-used Antiretroviral 2 Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis.

S. Khoo, S. Parikh, P. Denti, 2020 .

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.

High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis

S. Khoo, G. Davies, E. Corbett, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases

Joseph M. Sheridan, Saye Khoo, Jonathan R. Heal, 2021, J. Chem. Inf. Model..

Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2008, Antiviral therapy.

T cell Homeostatic Imbalance in Placentae from Women with HIV in the absence of Vertical Transmission.

L. Myer, C. Gray, S. Khoo, 2021, The Journal of infectious diseases.

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

S. Khoo, A. Owen, D. Back, 2014, Pharmacogenetics and genomics.

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

C. Marzolini, S. Khoo, D. Back, 2016, The Journal of antimicrobial chemotherapy.

Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults

S. Khoo, D. Terlouw, D. Lalloo, 2018, Antimicrobial Agents and Chemotherapy.

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

S. Khoo, A. Owen, M. Siccardi, 2017, Antimicrobial Agents and Chemotherapy.

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort

K. Seden, S. Khoo, S. Kimaiyo, 2011, PloS one.

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy

S. Khoo, D. Terlouw, D. Lalloo, 2018, Antimicrobial Agents and Chemotherapy.

Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretroviral therapy

S. Khoo, Dianne J Terlouw, M. Mukaka, 2018, bioRxiv.

Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults

S. Khoo, D. Terlouw, D. Lalloo, 2018, Antimicrobial Agents and Chemotherapy.

A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin

P. Kaleebu, S. Khoo, F. Chiodi, 2023, AIDS.

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

K. Hood, B. Jani, S. Khoo, 2023, BMJ open.

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

Darren L. Smith, S. Khoo, A. Owen, 2010, Antimicrobial Agents and Chemotherapy.

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)

C. Leen, A. Winston, C. Sabin, 2014, HIV medicine.

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF☆

C. Leen, M. Pirmohamed, L. Haddow, 2016, Cytokine.

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing

S. Khoo, M. Chaponda, A. Riordan, 2016, AIDS.

A Multiple Dose Phase 1 Assessment of Rilpivirine Long-Acting in a Model of Pre-Exposure Prophylaxis against HIV.

Ross D. Cranston, Kaleab Z. Abebe, S. Khoo, 2019, AIDS research and human retroviruses.

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

C. Marzolini, S. Khoo, Catherine E Moss, 2019, Clinical Pharmacokinetics.

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

Ross D. Cranston, Kaleab Z. Abebe, S. Khoo, 2016, The lancet. HIV.

S. Khoo, R. Heyderman, N. Klein, 2019, The Journal of infectious diseases.

The effect of changing to Bictegravir on lipids using real world data: A brief report

S. Khoo, T. Heseltine, S. Murray, 2022, Journal of clinical pharmacy and therapeutics.

Potential implications of CYP 3 A 4 , CYP 3 A 5 and MDR-1 genetic variants on the efficacy of Lopinavir / Ritonavir ( LPV / r ) monotherapy in HIV-1 patients

H. Jessen, A. Winston, D. Cooper, 2022 .